| Identification | Back Directory | [Name]
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol | [CAS]
105565-56-8 | [Synonyms]
BMY-14802 >=97% (HPLC)
1-Piperazinebutanol, α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol | [Molecular Formula]
C18H22F2N4O | [MDL Number]
MFCD00899512 | [MOL File]
105565-56-8.mol | [Molecular Weight]
348.39 |
| Chemical Properties | Back Directory | [Boiling point ]
520.8±60.0 °C(Predicted) | [density ]
1.256±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
14.28±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BMY 14802 is a sigma-1 receptor (σ1R) antagonist, as well as an agonist at serotonin (5-HT) 1A and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM[1][2]. | [Definition]
ChEBI: 1-(4-fluorophenyl)-4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-butanol is a N-arylpiperazine. | [in vivo]
BMY 14802 (15 mg/kg; i.p.; single dose) significantly inhibits AIM and decreases dyskinesias, especially in the first hour in rat PD model[1][2].
| [IC 50]
Sigma 1 Receptor; 5-HT1A Receptor; α1-adrenergic receptor | [References]
[1] Paquette MA, et al. The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl). 2009 Jul;204(4):743-54. DOI:10.1007/s00213-009-1505-8
[2] Paquette MA, et al. Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias. Neuroreport. 2008 Jan 8;19(1):111-5. DOI:10.1097/WNR.0b013e3282f3b0d1 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|